Abstract
This paper gives an overall view of biotechnology products in China including drug legislation, classification of new drugs, and registration of biotechnology products. Special attention is given to the issues and concerns in the evaluation of new biotechnology products for approval in China.
Get full access to this article
View all access options for this article.